Head to Head Survey: Biomerica (NASDAQ:BMRA) vs. Anteris Technologies Global (NASDAQ:AVR)

Biomerica (NASDAQ:BMRA – Get Free Report) and Anteris Technologies Global (NASDAQ:AVR – Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, profitability, risk, dividends and earnings.

Profitability

This table compares Biomerica and Anteris Technologies Global’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Biomerica -115.50% -142.81% -77.83%
Anteris Technologies Global -4,637.48% -57.15% -50.73%

Volatility and Risk

Biomerica has a beta of 0.41, indicating that its share price is 59% less volatile than the S&P 500. Comparatively, Anteris Technologies Global has a beta of 2.02, indicating that its share price is 102% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Biomerica and Anteris Technologies Global, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Biomerica 1 0 0 0 1.00
Anteris Technologies Global 1 1 3 0 2.40

Biomerica presently has a consensus target price of $9.00, indicating a potential upside of 581.82%. Anteris Technologies Global has a consensus target price of $13.75, indicating a potential upside of 141.23%. Given Biomerica’s higher possible upside, research analysts plainly believe Biomerica is more favorable than Anteris Technologies Global.

Insider & Institutional Ownership

22.3% of Biomerica shares are held by institutional investors. 12.3% of Biomerica shares are held by insiders. Comparatively, 4.5% of Anteris Technologies Global shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Valuation and Earnings

This table compares Biomerica and Anteris Technologies Global”s gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Biomerica $4.45 million 0.92 -$3.78 million ($1.64) -0.80
Anteris Technologies Global $2.33 million 238.30 -$94.14 million ($1.61) -3.54

Biomerica has higher revenue and earnings than Anteris Technologies Global. Anteris Technologies Global is trading at a lower price-to-earnings ratio than Biomerica, indicating that it is currently the more affordable of the two stocks.

About Biomerica

(Get Free Report)

Biomerica, Inc. is a medical diagnostic company that develops, manufactures and markets in vitro diagnostic products. Its tests are designed to help detect and assess a range of health conditions, with a focus on gastrointestinal disorders, food sensitivities and related areas. The company’s offerings include laboratory-based and point-of-care tests, including its inFoods IBS blood test, which is intended to help guide dietary management for people with irritable bowel syndrome. Biomerica also sells diagnostic products for other applications, including infectious and inflammatory conditions.

About Anteris Technologies Global

(Get Free Report)

Anteris Technologies Global is a medical technology company focused on developing treatments for structural heart disease, particularly aortic valve conditions. Its work centers on transcatheter heart valve technology, which is designed to replace a damaged valve through a minimally invasive procedure. The company’s lead product is the DurAVR transcatheter heart valve. It is made using Anteris’ ADAPT tissue technology, which processes bovine pericardial tissue for use in medical devices. The valve is designed to resemble the structure and function of a healthy aortic valve.

Receive News & Ratings for Biomerica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biomerica and related companies with MarketBeat.com's FREE daily email newsletter.